Autolus Therapeutics Presents Preclinical Data on AUT06NG at the SITC Annual Meeting
November 09 2019 - 7:00AM
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies for the treatment of cancer, today presented
pre-clinical data on AUTO6NG, the company’s next generation
GD2-targeting CAR (chimeric antigen receptor) T cell therapy, at
the 34th Annual Meeting of the Society for Immunotherapy of Cancer
(SITC) being held November 6-10, 2019, in Washington, D.C.
“Autolus’ growing set of programming
modules addresses a range of inhibitory factors within the
highly complex and dynamic solid tumor microenvironment.
This presentation demonstrates the utility of three modules added
to the clinically active and validated AUTO6 GD-2 targeting CAR
that not only improve CAR T persistence but also combat the
immunosuppressive environment,” said Dr. Christian Itin, chairman
and chief executive officer of Autolus. “Based on these
encouraging pre-clinical results, which demonstrate the activity of
AUTO6NG, we plan on initiating a clinical study in patients with
GD2 positive tumors including refractory/relapsed neuroblastoma in
the second half of next year.”
AUTO6NG: Next generation GD2-targeting
CAR T-cell therapy with improved persistence and insensitivity to
TGFBeta and checkpoint inhibition for relapsed/refractory
neuroblastoma, Achkova, D., et al. (Abstract number P146, poster
presentation, 7:00 am – 8:30 pm Eastern Time on
Saturday, November 9)
AUTO6 had previously shown clinical responses
without inducing neurotoxicity in pediatric patients with r/r
neuroblastoma (Straathof et al., AACR 2018). Building on
AUTO6, additional programming modules were introduced forming
AUTO6NG to help the CAR T cells persist in and withstand the
hostile tumor microenvironment. AUTO6NG is a GD2-targeted CAR
T transduced with modules encoding either an IL7 chimeric cytokine
receptor (IL7R_CCR) to increase persistence, or a dominant negative
TGFβRII (dnTGFbRII) protein to block inhibitor signals from TGFβ
and a truncated SHP2 (dSHP2) protein designed to block inhibitor
signals from PD1. Both single and dual transduced CAR T cells
were evaluated in vitro for anti-tumor activity, cytokine
secretion, T cell proliferation, survival and resistance to
immunosuppressive pathways. The addition of IL7R_CCR,
dnTGFbRII and dSHP2 modules to the AUTO6NG product augment its
functions by extending T-cell persistence and rendering modified
T-cells resistant to TGFβ- and PD1/PDL1-driven immune inhibition in
vitro. Additionally, intravenous delivery of AUTO6NG in NSG
mice with established tumor burden exhibited potent anti-tumor
activity and extended survival, whereas AUTO6 showed no activity in
that model.
About AUTO6NGAUTO6NG is a next
generation programmed T cell product candidate in pre-clinical
development. AUTO6NG builds on preliminary proof of concept
data from AUTO6, a CAR in clinical development for the treatment of
neuroblastoma, which can target GD2-expressing cancers with a
chimeric antigen receptor (CAR). AUTO6NG incorporates
additional cell programming modules to augment its functions by
extending persistence and rendering modified T-cells resistant to
immune inhibition. With the enhanced properties of AUTO6NG,
it may be suitable for the treatment of GD2-expressing solid
tumors, including neuroblastoma, osteosarcoma, melanoma, small cell
lung cancer, and soft tissue sarcoma.
About Autolus Therapeutics
plcAutolus is a clinical-stage biopharmaceutical company
developing next-generation, programmed T cell therapies for the
treatment of cancer. Using a broad suite of proprietary and
modular T cell programming technologies, the company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus
has a pipeline of product candidates in development for the
treatment of hematological malignancies and solid tumors. For
more information please visit www.autolus.com.
Forward-Looking StatementThis
press release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are
statements that are not historical facts, and in some cases can be
identified by terms such as “may,” “will,” “could,” “expects,”
“plans,” “anticipates,” and “believes.” These statements
include, but are not limited to, statements regarding Autolus’
financial condition and results of operations, as well as
statements regarding the anticipated development of Autolus’
product candidates, including its intentions regarding the timing
for providing further updates on the development of its product
candidates, and the sufficiency of its cash resources. Any
forward-looking statements are based on management's current views
and assumptions and involve risks and uncertainties that could
cause actual results, performance or events to differ materially
from those expressed or implied in such statements. For a
discussion of other risks and uncertainties, and other important
factors, any of which could cause our actual results to differ from
those contained in the forward-looking statements, see the section
titled “Risk Factors” in Autolus' Annual Report on Form 20-F filed
on November 23, 2018 as well as discussions of potential risks,
uncertainties, and other important factors in Autolus' future
filings with the Securities and Exchange Commission from time to
time. All information in this press release is as of the date
of the release, and the company undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events, or otherwise, except as required
by law.
Investor and media contact:Silvia
TaylorVice President, Corporate Affairs and
CommunicationsAutolus+1-240-801-3850s.taylor@autolus.com
UK:Julia Wilson+44 (0) 7818 430877j.wilson@autolus.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Apr 2023 to Apr 2024